Anesthesia: Essays and Researches  Login  | Users Online: 4992 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Home | About us | Editorial board | Ahead of print | Search | Current Issue | Archives | Submit article | Instructions | Copyright form | Subscribe | Advertise | Contacts
Year : 2021  |  Volume : 15  |  Issue : 4  |  Page : 457-459

Myasthenia gravis and COVID-19 – A clinical checkmate

Department of Anaesthesiology and Critical Care, Indira Gandhi Medical College and Research Institute, Puducherry, India

Correspondence Address:
Dr. Vijayalakshmi Sivapurapu
Plot No 7 and 8, Ground Floor, Logu Nagar, Gorimedu, Puducherry - 605 006
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aer.aer_129_21

Rights and Permissions

Myasthenia gravis (MG) patients with coronavirus disease (COVID-19) pose a unique challenge for intensive care management. Higher risk of infection is observed in patients with MG due to the immunosuppressant medications they are prescribed. The underlying component of respiratory muscle weakness predisposes these patients to experience a more severe form of illness. In the case of diagnosis of COVID-19 in MG patients, judicious continuation of immunosuppressants, avoiding drugs that worsen MG along with the continuation of cholinesterase inhibitors is prudent. Early diagnosis in cases with high-index of suspicion, extra precautions, COVID-appropriate behavior, and early immunization is paramount for the health of MG patients during this pandemic.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded96    
    Comments [Add]    

Recommend this journal